Complementary and Alternative Medicine:

Does it work? Is it safe? Why are so many people using it?

By Ellen Hughes, M.D.

Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. *JAMA* 1998; 280: 1569-1575.

2. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. *N Engl J Med* 1993; 328:246-252
3. Astin JA. Why patients use alternative medicine: results of a national study. *JAMA* 1998; 279:1548-1553.
4. Pelletier K, Marie A, Krasner M. et al. Current trends in the integration and reimbursement of complementary and alternative medicine by managed care,insurance carriers, and hospital providers. *Am J Health Promotion* 1997; 12:112-123.
5. Dietary Supplement Health and Education Act of 1994. (Public Law 103-417, §2, 108 Stat. 4325).
6. Ernst E. Harmless herbs? A review of the recent literature. *Am J Med* 1998; 104:170-178.

DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biological activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. *N Engl J Med* 1998; 339:785-791.

8. Piscitell SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John's wort. *Lancet* 2000; 355:547-548.
9. Anon. Drug interactions with St. John's wort. *Medical Letter* 2000; 42:56
10. Angell M, and Kassirer JP. Alternative medicine-the risks of untested and unregulated remedies. *N Engl J Med* 1998; 339:839-841. Editorial.

Keeping Up with the Top Selling Herbs

By Cathi Dennehy, Pharm.D.

1. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. *JAMA* 1998; 280:1569-1575.
2. Blumenthal M. Herb market levels after five years of boom: 1999 sales in mainstream market up only 11% in first half of 1999 after 55% increase in 1998. *Herbalgram* 1999; 47:64-65.
3. Schulz V, Hansel R, Tyler VE. Rational phytotherapy: a physician's guide to herbal medicine. Berlin, Heidelberg: Springer-Verlag, 1998.
4. Krest I, Keusgen M. Quality of herbal remedies from Allium sativum: Differences between allinase from garlic powder and fresh garlic. *Planta Med* 1999; 65:139-143.
5. Berthold HK, Sudhop T. Prevention of atherosclerosis. *Curr Opin Lipidol* 1998; 9:565-569.
6. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol – meta-analysis. *Ann Intern Med* 1993; 119:599-605.
7. Neil HAW, Silagy C. Garlic as a lipid lowering agent – a meta-analysis. *J R Coll Physicians Lond* 1994; 28(1):39-44.
8. Neil HAW, Silagy CA, Lancaster T et al. Garlic powder in the treatment of moderate hyperlipidemia: a controlled clinical trial and meta-analysis. *J R Coll Physicans Lond* 1996; 30(4):329-334.
9. Steiner M, Khan AH, Holbert D et al. A double blind cross-over study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. *Am J Clin Nutr* 1996; 64:866-870.
10. Adler AJ, Holub BJ. Effect of garlic and fish oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. *Am J Clin Nutr* 1997; 65:445-450.
11. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism *JAMA.* 1998; 279(23):1900-1902.
12. Isaacsohn JL, Moser M, Stein EA et al. Garlic powder and plasma lipids and lipoproteins – A multicenter, randomized, placebo-controlled trial. *Arch Intern Med* 1998; 158:1189-1194.
13. Silagy CA, Neil HAW. A meta-analysis of the effect of garlic on blood pressure. *J Hyperten* 1994; 12:463-468.

14. Koscielny J, KluBendorf D, Latza R et al. The antiatherosclerotic effect of Allium sativum. *Atherosclerosis* 1999; 144:237-249.

15. Orekhov AN, Grunwald J. Effects of garlic on atherosclerosis. *Nutrition* 1997; 13:656-663.

16. Sitrija S, Plengvidhya C, Kangkaya V et al. Garlic and diabetes mellitus phase II clinical trial. *J Med Ass Thai* 1987; 70 (Suppl 2): 223-227

17. Mansell P, Reckless PD, Lloyd L. The effect of dried garlic powder tablets on serum lipids in non-insulin dependent diabetic patients. *Eur J Clin Res.* 1996; 8:25-26.

18. Pitchumoni SS, Doraiswamy PM. Current status of antioxidant therapy for Alzheimer's Disease. *JAGS* 1998; 46:1566-1572.

19. Smith PF, Maclennan K, Darlington C. The neuroprotective properties of Ginkgo biloba leaf: a review of the possible relationship to platelet activating factor (PAF). *J Ethnopharmacol* 1996; 50:131-139.

20. Chen X, Salwinski S, Lee TJ-F. Extracts of ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. *Clin Exper Pharmacol Pysiol* 1997; 24:958-959.

21. Kristofikova I, Klaschka J. In vitro effect of ginkgo biloba extract on the activity of pre-synaptic cholinergic nerve terminals in rat hippocampus. *Dement Geriatr Cogn Disord* 1997; 8:43-48.

22. Marcilhac A, Dakine N, Bourhim N et al. Effect of chronic administration of ginkgo biloba extract or ginkgolide on the hypothalamic-pituitary adrenal axis in the rat. *Life Sci.* 1998; 62:2329-2340.

23. Brunello N, Racagni G, Clostre F et at. Effect of an extract of ginkgobiloba on noradrenergic systems of rat cerebral cortex. *Pharmacol Res Commun.* 1985; 17:1063-1072.

24. Pietri S, Seguin JR, d'Argigny P et al. Ginkgo biloba extract (EGb761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery. *Cardiovasc Drugs Ther* 1997; 11:121-131.

25. Jung F, Mrowietz C, Kiesewetter H et al. Effect of ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. *Arnzneim Forsch/Drug Research* 1990; 40:589-593.

26. Le Bars PL, Katz MM, Berman N et al. A placebo-controlled, double-blind randomized trial of an extract of ginkgo biloba for dementias. *JAMA* 1997; 278:1327-1332.

27. Kanowski S, Herrmann WM, Stephan K et al. Proof of efficacy of the ginkgo biloba special extact EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Pharmacopsych* 1996; 29:47-56.

28. Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgo biloba on cognitive function in Alzheimer Disease. *Arch Neurol* 1998; 55:1409-1415.

29. Ernst E, Pittler MH. Ginkgo biloba for dementia: a systematic review of double-blind, placebo-controlled trials. 1999; 17(4):301-308.

30. Blume J, Kieser M, Holscher U. Placebo-controlled double-blind study of the effectiveness of ginkgo biloba special extract EGb 761 in patients with intermittent claudication. *VASA* 1996; 25:265-274.

31. Peters H, Kieser M, Holscher U. Demonstration of the efficacy of ginkgo biloba special extract Egb 761 on intermittent claudication – A placebo-controlled, double-blind multicenter trial. 1998; 27:106-110.

32. Anon. Ginkgo biloba. *Altern Med Rev* 1998; 3(1): 54-57.

33. Bennett DA, Phun L, Polk JF et al. Neuropharmacology of St John's wort (Hypericum). *Ann Pharmacother* 1998; 32:1201-1207.

34. Muller WE, Singer A, Wonnemann M et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. *Pharmacopsych* 1998; 31:16-21.

35. Linde K, Ramirez G, Mulrow CD et al. St John's wort for depression – an overview and meta-analysis of randomized clinical trials. *BMJ* 1996; 313:253-258.

36. Antonuccio DO, Danton WG, Denelsky GY et al. Raising questions about antidepressants. *Psychother Psychosom* 1999; 68:3-14.

37. Stevinson C, Ernst E. Hypericum for depression: An update of the clinical evidence. *Eur Neuropsychopharm* 1999; 9:501-505.

38. Williams JW, Mulrow C, Chiquette E et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. *Ann Int Med.* 2000; 132:743-756.

39. Harrer G, Schmidt U, Kuhn U et al. A comparison of equivalence between St John's wort extract LoHyp-57 and fluoxetine. *Arzneim-Forsch/Drug Res* 1999; 49:289-296.

40. Brenner R, Azbel V, Subramoniam M et al. Comparision of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. *Clin Therap.* 2000; 22:411-419

41. Schrader E. Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. *Int J ClinPsychopharmacol.* 2000; 15:61-68.

42. Ernst E, Rand JI, Barnes J et al. Adverse effects profile of the herbal antidepressant St John's wort (*Hypericum perforatum L.*). *Eur J Clin Pharmacol* 1998; 54:589-594.

43. Lantz M, Buchalter E, Giambanco V. St John's wort and antidepressant drug interactions in the elderly. *J Geriatr Psychiatry Neurol* 1999; 12:7-10.

44. Nierenberg AA, Burt T, Matthews J et al. Mania associated with St John's wort. *Biol Psych* 1999; 46(12):1707-1708.

45. Ernst E. Second thoughts about safety of St John's wort. *Lancet* 1999; 354:2014-2015.

46. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St. John's wort. *Lancet*. 2000; 355:547-548.

47. Tatro D. Drug interactions with St. John's wort. *Drug Facts Comparisons NEWS*. May 2000; 34-38.

48. Markowitz JS, DeVane CL, Boulton DW et al. Effect of St. John's wort (*Hypericum Perforatum*) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. *Life Sci*. 2000; 66:133-139

49. Singh Y. Kava: an overview. *J Ethnopharmacology* 1992; 37:13-45.

50. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. *Pharmacopsychiatry* 1997; 30:1-5.

51. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from *Piper methysticum* as modulator of the GABA binding site in different regions of rat brain. *Psychopharmacology* 1994; 116:469-474.

52. Schirrmacher K, Busselberg D, Langosch JM et al. Effects of kavain on voltage-activated inward currents of dorsal root ganglion cells. *Eur Neuropsychopharmacol* 1999; 9:171-176.

53. Gleitz J, Friese J, Beile A et al. Anticonvulsive action of kavain estimated from its properties on stimulated synaptosomes and Na channel receptor sites. *Eur J Pharmacol* 1996; 315:89-97.

54. Seitz U, Schule A, Gleitz J. Monoamine uptake inhibition properties of kava pyrones. *Planta Med* 1997; 63:548-549.

55. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. *Prog Neuro-psychopharmacol Biol Psychiat* 1998; 22:1105-1120.

56. Munte TF, Heinze HJ, Matzke M et al. Effects of oxazepam and an extract of kava roots (*Piper methysticum*) on event-related potentials in a word recognition task. *Neuropsychobiol* 1993; 27:46-53.

57. Heinze HJ, Munthe TF, Steitz J et al. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. *Pharmacopsychiatry* 1994; 27:224-230.

58. Duffield PH, Jamieson D. Development of tolerance to kava in mice. *Clin Exp Pharmacol Physiol* 1991; 18:571-578.47.

59. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol on subjective measures of impairment and intoxication and on cognitive performance. *Drug Alcohol Rev* 1997; 16:147-155.

60. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. *Ann Intern Med* 1996; 125(11):940-941.

61. Schelosky L, Raffauf C, Jendroska K et al. Kava and dopamine antagonism. *Neurol Neurosurg Psych* 1995; 58(5):639-640.

62. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. *Urology* 1996; 48(1):12-20.

63. Bayne CW, Donnelly F, Ross M et al. Serenoa repens (Permixon®): A 5-alpha reductase Types 1 and II inhibitor – new evidence in a coculture model of BPH. *Prostate* 1999; 40:232-241.

64. Paubert-Braquet M, Mencia Huerta JM, Cousse H et al. Effect of the lipidic lipidosterolic extract of Serena repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B_4 (LTB_4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997; 57(3):299-304.

65. Paubert-Braquet M, Richardson FO, Servent-Saez N et al. Effect of the lipidosterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor induced proliferation of cultures of human prostate biopsies. *Eur Urol* 1998; 33:340-347.

66. Goepel M, Hecker U, Krege S et al. Saw palmetto extracts potently and non-competitively inhibit human alpha-1 adrenoreceptors in vitro. *Prostate* 1999; 38:208-215.

67. Wilt T, Ishani A, Stark G et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia. *JAMA* 1998; 280(18):1604-1609.

68. Plosker GL, Brogden RN. Serenoa repens (Permixon®) - A review of its pharmacology and therapeutic efficacy in benign prostatic hypertrophy. *Drugs Aging* 1996; 9(5):379-395.

69. Carraro JC, Raynaud JP, Koch G et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. *Prostate* 1996; 29:231-240.

70. Anon. Potential herb-drug interactions. *Rev Nat Prod* Dec 1998; 1-8.

71. Israelsen LD, Blumenthal M. FDA issues final regulations regarding structure/function claims for dietary supplements under DSHEA. *Herbalgram*. 2000; 48:32-38.

72. Bahrke MS, Morgan WP. Evaluation of the ergogenic properties of ginseng. *Sports Med* 1994; 18(4):229-248.

73. Liu C-X, Xiao P-G. Recent advances on ginseng research in China. *J Ethnopharmacol* 1992; 36:27-38.

74. Allen JD, McLung J, Nelson AG et al. Ginseng supplementation does not enhance healthy young adults peak aerobic exercise performance. *J Am Coll Nutr* 1998; 17(5):462-466.

75. Sorenson H, Sonne J. A double-masked study of the effects of ginseng on cognitive functions. *Curr Ther Res* 1996; 57(12):959-968.

76. D'Angelo L, Grimaldi R, Caravaggi M et al. A double-blind, placebo-controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers. *J Ehnopharmacol* 1986; 16:15-22.

77. Marasco C, Ruiz V, Villagomez S et al. Double-blind study of a multivitamin complex supplemented with ginseng extract. *Drugs Exp Clin Res* 1996; 22(6):323-329.

78. Scaglione F, Cattaneo G, Alessandria M et al. Efficacy and safety of a standardized ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold. *Drugs Exp Clin Res* 1996; 22(2):65-72.

79. Siegel RK. Ginseng abuse syndrome. *JAMA.* 1979; 241(15):1614-1615.

80. Greenspan E. Ginseng and vaginal bleeding. *JAMA* 1983; 249(15):2018.

81. Punnonen R, Lukola A. Estrogen-like effect of ginseng. *BMJ* 1980; 281:1110.

82. Wilkie A, Cordess C. Ginseng-a root just like a carrot? *J R Soc Med* 1994; 87(10):594-595.

83. Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: report of a possible cause. *J Clin Psychopharmacol* 1995; 15(6):447-448.

84. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulin dependent diabetic patients. *Diabetes Care* 1995; 18(10):1373-1375.

85. McRae S. Elevated digoxin levels in a patient taking digoxin and Siberian ginseng. *Can Med Assoc J* 1996; 155(3):293-295.

86. Awang DVC. Siberian ginseng toxicity may be case of mistaken identity. *Can Med Assoc J* 1996; 155(9):1237.Letter.

87. Becker BN, Greene J, Evanson J et al. Ginseng-induced diuretic resistance. *JAMA* 1996; 276(8):606-607.

88. Wagner H. Herbal immunostimulants for the prophylaxis and therapy of colds and influenza. *Eur J Herb Med* 1997; 3:22-30.

89. Parnam MJ. Benefit-risk assessment of the squeezed sap of the purple coneflower (Echinacea pupurea) for long term oral immunostimulation. *Phytomed* 1996; 3(1):95-102.

90. Elasser-Beile U, Willenbacher W, Bartsch HH et al. Cytokine production in leukocyte cultures during therapy with Echinacea extract. *J Clin Lab Anal* 1996; 10:441-445.

91. Burger RA, Torres AR, Warren RP et al. Echinacea induced cytokine production by human macrophages. *Int J Immunopharmac* 1997; 19(7):371-379.

92. O'Hoheisel MD, Sandberg S, Bulitta M et al. Echinagard treatment shortens the course of the common cold: a double-blind, placebo-controlled trial. *Eur J Clin Res* 1997; 9:261-268.

93. Brinkeborn RM, Shah DV, Degenring FH. Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold. *Phytomed* 1999; 6(1):1-5.

94. Melchart D, Walther E, Linde K, et al. Echinacea root extracts for the prevention of upper respiratory tract infections. *Arch Fam Med* 1998; 7:541-545.

95. Grimm W, Hans-Helge M. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. *Am J Med* 1999; 106:138-143.

96. Mullins RJ. Echinacea-associated anaphylaxis. *MJA* 1998; 168:170-171.

97. Liske E. Therapeutic efficacy and safety of *Cimicifuga racemosa* for gynecologic disorders. *Adv Ther* 1998; 15(1):45-53.

98. Struck D, Tegtmeier M, Harnischfeger G. Flavones in extracts of *Cimicifuga racemosa. Planta Med* 1997; 63:289.

99. Jarry H, Harnischfeger G, Duker E. Studies on the endocrine effects of the contents of *Cimicifuga racemosa*, II: *in vitro* binding of compounds to estrogen receptors. *Planta Med* 1985; 4:316-319.

100. Duker E, Kopanski L, Jarry H et al. Effect of extracts of *Cimicifuga racemosa* on gonadotropin release in menopausal women and ovariectomized rats. *Planta Med* 1991; 57:420-424.

101. Einer-Jensen N, Zhao J, Andersen KP et al. *Cimicifuga* and *Melbrosia* lack estrogenic effects in mice and rats. *Maturitas* 1996; 25:149-153.

102. Liske E, Wustenberg P. Therapy of climacteric complaints *with Cimicifuga racemosa*: herbal medicine with clinically proven evidence. *Menopause* 1998; 5:250.

103. Foster S. Black cohosh: a literature review. *Herbalgram* 1999; 45:35-50.

104. Blumenthal M, Busse WR (Eds). The complete German Commission E monographs: therapeutic guide to herbal medicines. Boston: American Botanical Council. Integrative Medicine Communications, 1998.

Dietary Supplements: Sorting Through the Evidence

By Candy Tsourounis, Pharm.D.

1 Hatoum HT, Kania CM, Kong SX et al. Prevalence of insomnia: a survey of the enrollees at five managed care organizations. *Amer J Man Care* 1998; 4:79-86.

2. Morin CM, Colecchi C, Stone J et al. Behavioral and pharmacological therapies for late-life insomnia. *JAMA* 1999; 281:991-99.

3. Garfinkel D, Laudan M, Nof D, et.al. Improvement of sleep quality in elderly people by controlled-release melatonin. *Lancet.* 1995; 346:54-44

4. Dahlitz M, Alvarez B, Vignaut J, et.al. Delayed sleep phase response to melatonin. *Lancet.* 1991 337:1121-24

5. Haimov I, Lavie P, Laudan M, et.al. Melatonin replacement therapy in elderly insomniacs. *Sleep.* 1995; 18:598-603

6. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. *Sleep* 1998; 21:52-68.

7. Petrie K, Dawson AG, Thompson L et al. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. *Biol Psychiatry* 1993; 33:526-30.

8. Petrie K, Conaglen JV, Thompson L et al. Effect of melatonin on jet lag long haul flights. *BMJ* 1989; 298:705-5.

9. Claustrat B, Brun J, David M et al. Melatonin and jet lag: confirmatory result using a simplified protocol. *Biol Psychiatry* 1992; 32:705-

10. Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of a controlled double blind study. *BMJ* 1986; 292:1170.

11. Arendt J, Aldhous M, English J et al. Some effects of jet lag and their alleviation by melatonin. *Ergonomics* 1987; 30:1379-93.

12. Spitzer RL, Terman M, Williams JBW et al. Jet-lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. *Am J Psychiatry* 1999; 156:1392-96.

13. Bardazzi F, Placucci F, Neri I. Fixed drug eruption due to melatonin. *Acta Derm Venereol* 1997; 78:69-70.

14. Force RW, Hansen L, Bedell M. Psychotic episode after melatonin. *Ann Pharmacother* 1997; 31:1408.

15. Brzezinski A, Lynch HJ, Seibel MM et al. The circadian rhythm of plasma melatonin during the normal menstrual cycle and in amenorrheic women. *J Clin Endocrinol Metab* 1988; 66:891-895.

16. Hahm H, Kujawa J and Ausburger L. Comparison of melatonin products against USP's nutritional standards and other criteria. *J Amer Pharm Assoc*. 1999; 39:27-31.

17. Waldhauser F, Waldhauser M, Lieberman HR et al. Bioavailability of oral melatonin in humans. *Neuroendocrinology* 1984; 39:307-313.

18. Cumming GJ, Handley CJ, Preston BN. Permeability of composite chondrocyte-culture millipore membranes to solutes of varying size and shape. *Biochem J* 1979; 181:257-66.

19. McAlindon TE, et al. Glucosamine and chondrotin for treatment of osteoarthritis. A systematic quality assessment and meta-analysis. *JAMA* 2000;283:1469-74.

20. Reichelt A, Forster KK, Fischer M et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomized, placebo-controlled, double-blind study. *Arzneim-Forsch* 1994; 44:75-80.

21. Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. *Clin Ther* 1980; 3:260-72.

22. Houpt JB, McMillan R, Wein C et al. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. 1999; 26:2423-30.

23. Leffler CT, Philippi AF, Leffler SG et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. *Mil Medicine* 1999; 164:85-91.

24. Karzel K, Domenjoz R. Effects of hexosamine derivatives and uronic acid derivative on glycosaminoglycan metabolism of fibroblast cultures. *Pharmacology* 1971; 5:337-345.

25. Almada AL, Harvey PW, Platt KJ. Effect of chronic oral glucosamine sulfate upon fasting insulin resistance index (FIRI) in nondiabetic individuals. (Abstract) Experimental Biology Conference, San Diego, April 19, 2000.

26. Vaz AL. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. *Curr Med Res Opin* 1982; 8:145-49.

27. Uebelhart D, Thonar EJM, Delmas PD et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. *Osteoarthritis Cartilage* 1998; 6:39-46.

28. Baici A, Horler D, Moser B et al. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. *Rheumatol Int* 1992; 12:81-88.

29. Conte A, de Bernardi M, Palmieri L et al. Metabolic fate of exogenous chondroitin sulfate in man. *Arzneim-Forsch* 1991; 41:768-772.

30. Conte A, Volpi N, Palmieri L et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. *Arzneim-Forsch* 1995; 45:918-925.

31. Bourgeois P, Chales G, Dehais J et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3x400 mg/day vs placebo. *Osteoarthritis Cartilage* 1998; 6:25-30.

32. Busci L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slowacting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. *Osteoarthritis Cartilage* 1998; 6:31-36.

33. Morreale P, Manopulo R, Galati M et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. *J Rheumatol* 1996; 23:1385-91

34. Fontenele JB, Araujo GB, Wilson J et al. The analgesic and anti-inflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent. *Biol Pharm Bull* 1997; 20:1151-54.

35. Shark cancers cast doubt on cartilage pill [press release]. Baltimore: Johns Hopkins University; April 5, 2000.

36. Pettit GR, Ode RH. Antineoplastic agents L: isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark Sphyrna lewini. *J Pharm Sci* 1977; 66:757-58.

37. Miller DR, Anderson GT, Stark JJ et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. *J Clin Oncol* 1998; 16:3649-55.

38. Ashar B, Vargo E. Shark cartilage induced hepatitis. *Ann Intern Med* 1996; 125:780-81.

39. Orentreich N et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *J Endocrinol Metab* 1984; 59:551-555.

40. Ebeling P et al. Physiological importance of dehydroepiandrosterone. *Lancet* 1994; 343:1479-81.

41. Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. *J Clin Endocrinol Metab* 1990; 71:696-704.

42. Casson PR, Faquin LC, Stentz FB et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. *Fertil Steril* 1995; 63:1027-31.

43. Wolkowitz OM, Reus VI, Keebler A et al. Double-blind treatment of major depression with dehydroepiandrosterone. *Am J Psychiatry* 1999; 156:4:646-49.

44. Usiskin KS et al. Lack of effect of DHEA in obese men. *Int J Obesity* 1990; 14:457-463.

45. Nestler JE et al. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. *J Clin Endocrinol Metab* 1988; 66:57-61.

46. Vogiatzi MG et al. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids and insulin resistance. *Metabolism* 1996; 45:1011-1015.

47. Van Vollenhoven RF et al. An open study of dehydroepiandrosterone in systemic lupus erythematosus. *Arthritis & Rheum* 1994; 37:1305-10.

48. Van Vollenhoven RF et al. Dehydroepiandrosterone in systemic lupus erythematosus. *Arthritis & Rheum* 1995; 38:1826-31.

49. Van Vollenhoven RF et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. *J Rheumatol* 1998; 25:285-89.

50. *Facts & Comparisions*, St. Louis 2000.

51. Reiter WJ et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. *Adult Urology* 1999; 53:590-595.

52. Flynn MA et al. Dehydroepiandrosterone replacement in aging humans. *J Clin Endocrinol Metab* 1999; 84:1527-1533.

53. Arlt W, Haas J, Callies F et al. Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. *J Clin Endocrinol Metab* 1999; 84:2170-76.

54. Morales AJ, Nolan JJ, Nelson JC et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. *J Clin Endocrinol Metab* 1994; 78:1360-67.

55. Casson PR et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-1 and decreases high-density lipoprotein: a six month trial. *Fertil Steril* 1998; 70:107-10.

56. Van Vollenhoven RF, Park JL, Genovese MC et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. *Lupus* 1999; 8:181-187.

57. Sahelian R, Borken S. Dehydroepiandrosterone and cardiac arrhythmia. *Ann Intern Med* 1998; 129:588.

58. Markowitz JS, Carson WH, Jackson CW. Possible dihydroepiandrosterone-induced mania. *Biol Psychiatry* 1999; 45:241-42.

59. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. *Biochimica et Biophysica Acta* 1995; 1271:195-204.

60. Digiesi V, Cantini F, Oradei A et al. Coenzyme Q10 in essential hypertension. *Molec Aspects Med* 1994; 15:S257-S263.

61. Langsjoen P, Langsjoen P, Willis R et al. Treatment of essential hypertension with coenzyme Q 10. *Molec Aspects Med* 1994; 15Supp:S265-S272.

62. Digiesi V, Cantini F, Bisi G et al. Mechanism of action of coenzyme Q10 in essential hypertension. *Curr Ther Res* 1992; 51:668-71

63. Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. *Curr Ther Res* 1990; 47:841-45.

64. Permanetter B, Rossy W, Klein G et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. *Eur Heart J* 1992; 13:1528-33.

65. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. *Proc Natl Acad Sci* 1985; 82:4240-44.

66. Morisco C, Nappi A, Argenziano L, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. *Molec Aspects Med* 1994; 15:S155-S163.

67. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. *Clin Investigator* 1993; 71:S134-6.

68. Watson PS, Scalia GM, Galbraith A et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. *J Amer Col Cardiol* 1999; 33:1549-52.

69. Khatta M, Alexander BS, Krichten CM, et. al. The effect of coenzyme Q10 in patients with congestive heart failure. *Ann Intern Med.* 2000;132:636-40.

70. Singh RB, Niaz MA. Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q 10 in patients with coronary artery disease: discovery of a new role. *Internat J Cardiol* 1999; 68:23-9.

71. Singh RB, Wander GS, Rastogi A et al. Randomized, double-blind, placebo-controlled trial of coenzyme Q 10 in patients with acute myocardial infarction. *Cardiovasc Drugs Ther* 1998; 12:347-53.

72. Kamikawa T, Kobayashi A, Yamashita T et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. *Am J Cardiol* 1985; 56:247-51.

73. Baggio E, Gandini R, Plancher AC et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. *Molec Aspects Med* 1994; 15:S287-S294.

74. Matthews PM, Ford B, Dandurand RJ et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. *Neurology* 1993; 43:884-90.

75. Laaksonen R, Ojala JP, Tikkanen MJ et al. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. *Eur J Clin Pharmacol* 1997; 46:313-317.

76. Feigin A, Kieburtz K, Como P. Assessment of coenzyme Q10 tolerability in Huntington's disease. *Movement Disorders*, 1996 May, 11(3):321-3.

77. Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. *Clin Invest* 1993; 71:S129-33.

78. Lowe AG, Critchley AJ, Brass A. Inhibition of glucose transport in human erythrocytes by ubiquinone Q10. *Biochimica et Biophysica Acta* 1991; 1069(2):223-8.

79. Eriksson JG, Forsen TJ, Mortensen SA et al. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. *Biofactors* 1999; 9:315-8.

80. Landbo C; Almdal TP. Interaction between warfarin and coenzyme Q10. *Ugeskrift Laeger*, 1998 May 25, 160(22):3226-7.

81. Ghirlanda G, Oradei A, Manto A et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. *J Clin Pharmacol* 1993; 33:226-229.

Potential for Harm

By Mary Chavez, Pharm.D.

1. Foster S, Tyler VE. Tyler's Honest Herbal. A Sensible Guide to the Use of herbs and Related Remedies. 4th Edition. New York, NY: The Haworth Herbal Press, 1999.
2. Allen JE. Herbal remedies may be harmful. The Arizona Republic. March 6, 2000:E1, E3.
3. Palmer ME. Dietary supplements: "natural" is not always safe. *Emer Med* 1998; 30:52-74.
4. Ernst E. Harmless herbs? A review of the recent literature. *Amer J Med* 1998; 104:170-178.
5. Drew AK, Myers SP. Safety issues in herbal medicine: implications for the health professions. *Med J Australia* 1998; 169:180-181.
6. Angell M, Kassirer JP. Alternative medicine: the risks of untested and unregulated remedies. *New Engl J Med* 1998; 339:839-841.
7. Frasca T, Brett AS, Yoo SD. Mandrake toxicity. A case of mistaken identity. *Arch Intern Med* 1997; 157:2007-2009.
8. Chan TY. Anticholinergic poisoning due to Chinese herbal medicines. *Vet Hum Toxicol* 1995; 37:156-157.
9. Slifman NR, Obermeyer WR, Aloi BK, et al. Contamination of botanical dietary supplements by *Digitalis lanata. New Engl J Med* 1998; 339:806-810.
10. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem J-L. Identification of aristolochic acid in Chinese herbs. *Lancet* 1994; 343:174. Letter.
11. Leikin JB, Paloucek FP. Poisoning & Toxicology Compendium with Symptoms Index. Hudson, OH: Lexi-Comp Inc. 1998.
12. Van Ypersele de Strihou C, Vanherweghem JL. The tragic paradigm of Chinese herbs nephropathy. *Nephrol Dial Transplant* 1995; 10:157-160. Editorial
13. Nortier JL, Martinez MC, Schmeiser HH et al. Urothelial carcinoma associated with the use of a Chinese herb (*Aristolochia fangchi*). *N Engl J Med* 2000; 342:1686-92.
14. Gertner E, Marshall PS, Dean Filandrinos, et al. Complications results from the use of Chinese herbal medications containing undeclared prescription drugs. *Arthritis Rheum* 1995; 38:614-617.
15. Keane FM, Munn SE, du Vivier AWP, et al. Analysis of Chinese herbal creams prescribed for dermatological conditions. *BMJ* 318:563-564.

16. Van Herweghem J-L, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. *Lancet* 1993; 341:387-391.
17. Diamond JR, Pallone TL. Acute interstitial nephritis following use of tung shueh pills. *Am J Kidney Dis* 1994; 24:219-221.
18. Abt AB, Oh JY, Huntington RA, Burkhart KK. Chinese herbal medicine induced acute renal failure. *Arch Intern Med* 1995; 155:211-212.
19. Farnsworth NR. Relative safety of herbal medicines. *HerbalGram* 1993; 29:36A-36H
20. Spriewald BM, Rascu A, Schaller KH, et al. Lead induced anaemia due to traditional Indian medicine: a case report. *Occup Environ Med* 1999; 56:282-283.
21. Hasegawa S, Nakayama K, Iwakiri K, et al. Herbal medicine-associated lead intoxication. *Intern Med* 1997; 36:56-58.
22. Jung BC, Morrissey-Ross M, Nicaj L, et al. Adult lead poisoning from an Asian Remedy for menstrual cramps--Connecticut, 1997. *MMWR* 1999; 48:27-29.
23. Lone AA. Botanical Products. American Society of Health-Systems Pharmacists. 34th Annual Midyear Clinical Meeting, http://www.medscape.com/Medscape/CNO/1999/ASHP/ASHP-03.html. Accessed 01-14-2000.
24. Chen HC, Hsieh MT, Chang SS, Liu SL. Long-term reno-cardiovascular effects of orally administered aconiti tuber in humans. *Am J Chin Med* 1990; 18:25-33.
25. Editor Herbal Rx: The promises and the pitfalls. *Consumers Report* 1999; 64:44-48.
26. ConsumersLab.com. Product review; Ginkgo biloba. http://www.consumerlab.com/results/ginkgobiloba.html. Accessed 11/24/1999.
27. Editor. Herbal Roulette. *Consumers Report* 1995; 60:698-705.
28. Monmaney, Terence. Labels' potency claims often inaccurate. Analysis Finds. *The Los Angeles Times*, August 31, 1998: A10.
29. ConsumersLab.com. Product review: Saw palmetto. http://www.consumlab.com/results/sawpalmeto.html. Accessed 3/8/2000.
30. Hahm H, Kujawa J and Ausburger L. Comparison of melatonin products against USP's nutritional standards and other criteria. *J Amer Pharm Assoc*. 1999; 39:27-31.
31. ConsumersLab.com. Product review: Glucosamine and chondrotin. http://www.consumlab.com/results/gluco.html. Accessed 3/9/2000.

32. Cupp MJ. Toxicology and Clinical Pharmacology of Herbal Products. Totowa, NJ: Humana Press, 2000.

33. DerMarderosian A. (Editor). Specific Herb-Drug Interactions. The Review of Natural Products. St. Louis, MO: Facts and Comparisons. Dec. 1998.

34. Fugh-Berman A. Herb-drug interactions. *Lancet* 2000; 355:134-138.

35. Gianni L, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. *US Pharmacists* 1998; May:80,83-84.

36. Cardinale V. How you and your patient can stay out of botanical trouble. *Drug Topics* 2000; 144: 70, 72.

37. DerMarderosian A. (Editor). Grapefruit. The Review of Natural Products. St. Louis, MO: Facts and Comparisons. June 1998.

38. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John's wort. *Lancet* 2000; 355:547-548.

39. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. *Lancet* 2000; 3553:548-549.

40. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. *Ann Pharmacother* 1999; 33:502.

41. Cupp MJ. Herbal remedies: adverse effects and drug interactions. *Amer Fam Physician* 1999; 59:1239-1244.

42. Brinker F. Herb Contraindications and Drug Interactions. 2nd edition. Sandy, OR: Eclectic Medical Publications. 1998.

43. Perharic L, Shaw D, Colbridge M, et al. Toxicological problems resulting from exposure to traditional remedies and food supplements. *Drug Safety*. 1994; 11:284-94.

44. Lin SH, Lin MS. A survey on drug related hospitalisation in a community teaching hospital. *Int J Clin Pharmacol Ther Toxicol* 1993; 31:66-69.

45. Schiano TD. Liver injury from herbs and other botanicals. *Clin Liver Disease* 1998; 2:608-631

46. DerMarderosian A. (Editor). Goldenseal. The Review of Natural Products. St. Louis, MO: Facts and Comparisons. Feb. 2000.

47. Mikkelsen SL, Ash KO. Adulterants causing false negatives in illicit drug testing. *Clin Chem* 1988; 34:2333-36.

Adverse Events Associated with Alternative Medicines – Recent Cases Reported to California Poison Control

By Christine A. Haller, M.D. and Thomas E. Kearney, Pharm.D., DABAT

1. Huxtable RJ. The myth of beneficent nature: The risks of herbal preparations. *Ann Intern Med* 1992; 117:165-166.
2. Cupp MJ. Herbal remedies: adverse effects and drug interactions. *Am Fam Physician* 1999; 59:1239-45.
3. Barrett B, Kiefer D., Rabago D. Assessing the risks and benefits of herbal medicine: an overview of scientific evidence. *Altern Ther Health Med* 1999; 5:40-49.
4. Woolf GM, Petrovic LM, Rojter SE et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. *Ann Intern Med.* 1994; 121:729-735.
5. Larrey D, Pageaux GP. Hepatotoxicity of herbal remedies and mushrooms. *Sem Liver Dis* 1995; 15:183-188.
6. Nightingale SL. New safety measures are proposed for dietary supplements containing ephedrine alkaloids. *JAMA* 1997; 278:15.
7. Chan TY, Critchley JA. Usage and adverse effects of Chinese herbal medicines. *Hum Exp Toxicol* 1996; 15:5-12.
8. The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines, Blumenthal editor, The American Botanical Council and Integrated Medicine Communications, Austin, TX 1998.
9. Almeida JC, Grimsley EW. Coma from the health food store: Interaction between kava and alprazolam. *Ann Intern Med* 1996; 125:940-941
10. Cott JM, Fugh-Berman A. Is St John's wort (*Hypericum perforatum*) an effective antidepressant ? *J Nerv Ment Dis* 1998; 186:500-01
11. Demott K. St John's Wort tied to serotonin syndrome. *Clinical Psychiatry News* 1998; 26:28
12. Lantz MS, Buchalter E, Giambanco V. St John's wort and antidepressant drug interactions in the elderly. *J Geriatr Psychiatr Neurol* 1999; 12:7-10
13. Fugh-Berman A. Herb-drug interactions. *Lancet* 2000; 355:134-38
14. Ernst E. Harmless Herbs? A review of the recent literature. *Am J Med* 1998; 104:170-178

15. Klepser TB,Klepser ME. Unsafe and potentially safe herbal therapies. *Am J Health-system Pharm* 1999; 56:125-38

16. The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines, Blumenthal editor, The American Botanical Council and Integrated Medicine Communications, Austin, TX 1998.

Inquiring Minds: Frequently Asked Consumer Questions About Herbs and Dietary Supplements

By Mitra Assemi, Pharm.D.

1. DCS. Health-trend survey: Consumers like Internet, alternative medicine; employers lukewarm on quality measurement. *AJSHP*. 1999:56:942-43.
2. Schulz V, Haensel R, Tyler VE (ed). *Rational Phytotherapy. A physician's guide to herbal medicine*. 3rd ed. Berlin: Springer Verlag; 1998.
3. Mitchell D. St. John's wort causes dangerous interaction with protease inhibitor. *Reuters Health*. [serial online]. February 11, 2000. Available at: www.reutershealth.com/cgi...news/closed/2000002/20000211.cle.meta. Accessed February 11, 2000.
4. .Johne A et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 1999; 66:338-45.
5. Anon. St. John's wort may interact with cyclosporin to cause heart transplant rejection. *Reuters Health*. [serial online]. February 16, 2000. Available at:http://muddy2.reutershealth.com/cgi…news/closed/200002/20000216clc.meta. Accessed February 16, 2000
6. Graham AS. Cytochrome P450 Drug Interactions. *Rx Consultant*. 1999; 8(2):1-8.
7. Gordon JB. SSRIs and St. John's wort: Possible toxicity? *Amer Fam Phys*. 1998; 57:950-51.
8. Mueller WE, Rolli M, Schaefer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopyschiat*. 1997; 30 (Suppl):102-07.
9. Simmen U et al. Hypericum perforatum inhibits the binding of mu- and kappa-opioid receptor expressed with the Semliki virus. *Pharmaceut Acta Helvetiae*. 1998; 73:53-56.
10. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. *AJHSP*. 1997; 54:692-93.
11. Henderson GL et al .Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. *Life Sci*. 1999; 65:209-14.
12. Shader RI, Greenblatt DJ. Phenelzine and the dream machine-ramblings and reflections. *J Clin Psychopharmacol* 1985; 5:65.
13. Gonzalez-Seijo JC et al. Manic episode and ginseng: report of a possible cause. *J Clin Psychopharmacol* 1995; 15:447-448.

14. Wilikie A, Cordess C. Ginseng- a root just like carrot? *J R Soc Med* 1994; 87:594-595.

15. Jung KY et al. Platelet activating factor antagonist activity of ginsenosides. *Biol Pharm Bull.* 1998; 21:79-80.

16. Park HJ, Lee JH, Song YB, Park KH. Effects of dietary supplementation of lipophillic fraction from *Panax ginseng* on cGMP and cAMP in rat platelets and on blood coagulation. *Biol Pharm Bull.* 1996; 19:1434-39.

17. Gillis CN. Panax ginseng pharmacology: A nitric oxide link? *Biochem Pharmacol.* 1997; 54:1-8.

18. Stolberg SGF. F.D.A. bans marketing of supplements to pregnant women. *New York Times.* [serial online] February 10, 2000. Available at: www.nytimes.com/yr/mo/day/ne...onal/science/hth-fda/pregnancy.html. Accessed February 10, 2000.

19. Tyler VE. *The Honest Herbal. A Sensible Guide to the Use of Herbs and Related Remedies.* 4th ed. Binghamtom,NY: Pharmaceutical Products Press; 1999.

20. Rasmussen WF, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. *Eur J Obstet Gyn Reproductive Biol.* 1990; 38:19-24.

21. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. *Pharmacotherapy.* 1999; 19:870-76.

22. Qi-bing M, Jing-yi T, Bo C. Advances in the pharmacological studies of Radix Angelica sinensis (Oliv) Diels (Chinese Danggui). *Chin Med J.* 1991; 104:776-81

23. Liske E, Wustenberg P. Therapy of climacteric complaints with *Cimicifuga racemosa*: herbal medicine with clinically proven evidence (abstract). *Menopause.* 1998; 5:250.

24. Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginal epithel. Doppelblindversuch Cimicifuga vs Oestrogenpraeparat. *Therapeutikon.* 1987; 1:23-31.

25. Nesselhut T, Schellhase C, Dietrich C, Kuhn W. Untersuchungen zur proliferativen Potenz von Phytopharmaka mit Oestrogenaehnlicher Wirkung bei Mammakarzinomzellen. *Gynakol Onkol.* 1993; 254:817-18.

26. Hirata JD et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. *Fertility Sterility.* 1997; 68:981-86.

27. Duda RB et al. pS2 expression induced by American ginseng in MCF-7 breast cancer cells. Ann Surg Oncol. 1996; 3:515-20.

28. Lauritzen CH et al. Treatment of premenstrual tension syndrome with *Vitex agnus castus*. Controlled, double-blind study versus pyridoxine. *Phytomed.* 1997; 4:183-89.

29. Chavez M. SAMe: S-adenosylmethionine. *AJHSP*. 2000; 57:119-23.

30. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: Molecular mechanisms and clinical implications. *Pharmcol Ther*. 1997; 73:265-80.

31. Harmand MF et al. Effects of S-adenosylmethionine on human articular chondrocyte differentiation: an in vitro study. *Amer J Med*. 1987; 83(Suppl5A):48-54.

32. Stramentinoli G. Pharmacological aspects of S-adenosylmethionine: pharmacokinetics and pharmacodynamics. *Amer J Med*. 1987; 83(Suppl5A):35-42.

33. Di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. *Amer J Med*. 1987; 83(Suppl5A):60-65.

34. Iruela LM, Minguez L, Merino J, Monedero G. Toxic interaction of S-adenosylmethionine and clomipramine. *Am J Psychiat*. 1993; 150:522.

Sources of Reliable Information on Alternative Medicine

By Mary J. Ferrill, Pharm.D.

1. Liberti LE, Der Marderosian A. Evaluation of commercial ginseng products. *J Pharm Sci* 1978; 67:1487-1489.
2. Anonymous. Melatonin. *Med Lett* 1995; 37:111-112.
3. Lamberg L. Melatonin potentially useful but safety, efficacy remain uncertain. *JAMA* 1996; 276:1011-1014.
4. Chuang W-C, Wu H-K, Sheu S-J, Chang H-C, Chen Y-P. A comparative study on commercial samples of ginseng radix. *Plant Med* 1995; 61:459-465.
5. Kujawa HH, Augsburger L. Comparison of melatonin products against USP's nutritional supplements standards and other criteria. *J Am Pharm Assoc* 1999; 39:27-31
6. Gebhart F. Study may have identified St. John's wort's power source. *Drug Topics* 1998; 142:47.

Legal Considerations Pertaining To Dietary Supplements

By Richard R.Abood, R.Ph., J.D.

1. Dietary Supplement Health and Education Act of 1994. (Public Law 103-417, §2, 108 Stat. 4325)
2. 21 U.S.C. §321(g)(1)
3. FDA Regulations on Statements Made for Dietary Supplements Concerning the Effect of the Product on Structure or Function of the Body: Final Rule. *Federal Register* 65:999-1000; 21 CFR Part 101. January 6, 2000.
4. Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999).P Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999).
5. 21 U.S.C. §321(m).
6. United States v. Guardian Chemical Corporation, 410 F.2d 157 (2nd Cir. 1969).
7. United States v. Kordel, 164 F.2d 913 (7th Cir. 1947).
8. 15 U.S.C. §45.
9. United States v. General Nutrition, Inc., No 94-686 (W.D.Pa. Apr. 28, 1994 consent decree.
10. Porter & Dietsch, Inc. v. Federal Trade Commission, 605 F.2d 294 (7th Cir. 1979).
11. Baker v. Arbor Drugs, Inc., 544 N.W.2d 727 (Mich. App. Ct. 1996).
12. In Meza v. Southern California Physicians Insurance Exchange, 1998 WL 134057 (Cal. App.3 Dist). (a physician's use of melaleuca oil, or tea tree oil, to treat a patient's wart, was held to be an intended use of the product within the drug definition, thus making the product an unapproved drug for the purpose of an insurance contract.)
13. Valentino JG, Bormel FG. Compounding botanicals: A legal perspective. JAPhA. 1999; 39:537.